{"id":366187,"date":"2023-09-26T11:02:08","date_gmt":"2023-09-26T09:02:08","guid":{"rendered":"https:\/\/medizinonline.com\/?p=366187"},"modified":"2023-09-29T15:26:18","modified_gmt":"2023-09-29T13:26:18","slug":"succes-therapeutique-grace-aux-pcsk9i","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/succes-therapeutique-grace-aux-pcsk9i\/","title":{"rendered":"Succ\u00e8s th\u00e9rapeutique gr\u00e2ce aux PCSK9i"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>L\u2019\u00e9volocumab (Repatha\u00ae), un inhibiteur de la PCSK9 (PCSK9i), a \u00e9t\u00e9 \u00e9valu\u00e9 jusqu\u2019\u00e0 ce jour dans 50&nbsp;\u00e9tudes cliniques contr\u00f4l\u00e9es impliquant plus de 51&nbsp;000 sujets [1]. Il a \u00e9galement montr\u00e9 une r\u00e9duction efficace \u00e0 long terme du LDL-C en conditions cliniques r\u00e9elles&nbsp;[2]. L\u2019extension de la limitation de l\u2019\u00e9volocumab permet \u00e0 un plus grand nombre de patient\u00b7e\u00b7s pr\u00e9sentant un risque cardiovasculaire (CV) \u00e9lev\u00e9 de b\u00e9n\u00e9ficier d\u2019un traitement par cet hypolip\u00e9miant*&nbsp;[3]. Le Prof. Dr m\u00e9d. Christian Schmied<a>,<\/a>&nbsp;Centre universitaire de cardiologie de Zurich et Hirslanden HerzGef\u00e4ssZentrum im Park, et le Dr m\u00e9d. Mohammed Barigou, Centre hospitalier universitaire vaudois (CHUV), discutent des r\u00e9sultats actuels de l\u2019\u00e9tude sur l\u2019\u00e9volocumab et de la place des PCSK9i dans la pr\u00e9vention CV en pratique clinique lors de ce d\u00e9bat d\u2019experts.<\/strong><\/p>\n\n\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fsucces-therapeutique-grace-aux-pcsk9i%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>L\u2019\u00e9volocumab (Repatha\u00ae), un inhibiteur de la PCSK9 (PCSK9i), a \u00e9t\u00e9 \u00e9valu\u00e9 jusqu\u2019\u00e0 ce jour dans 50&nbsp;\u00e9tudes cliniques contr\u00f4l\u00e9es impliquant plus de 51&nbsp;000 sujets [1]. Il a \u00e9galement montr\u00e9 une r\u00e9duction&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fsucces-therapeutique-grace-aux-pcsk9i%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":11,"featured_media":20531,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"0","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Rapport sp\u00e9cial \u2013 D\u00e9bat d\u2019experts: l\u2019\u00e9volocumab (Repatha\u00ae) sous la loupe","footnotes":""},"category":[11549,11315,11378,11404,11404,11378,11345,11549],"tags":[71101,32321,17963,32297,50151,71088,71089],"powerkit_post_featured":[],"class_list":["post-366187","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-medecine-interne-generale","category-cardiologie","category-endocrinologie-et-diabetologie","category-contenu-des-partenaires","tag-evolocumab-2","tag-evolocumab-fr","tag-hypercholesterolemie-fr","tag-inhibiteur-de-pcsk9","tag-ldl-c-fr","tag-pcsk9i","tag-repatha","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-01 19:44:10","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/366187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=366187"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/366187\/revisions"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=366187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=366187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=366187"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=366187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}